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Open access under the a b s t r a c t
In the search for new anti-cancer compounds, Brazilian Cerrado plant species have been investigated. The
hexane root bark extract of Kielmeyera coriacea lead to a mixture of d-tocotrienol (1) and its dimer (2). The
structures of both compounds 1 and 2 were established based on detailed 1D and 2D NMR and EI-MS
analyses. The cytotoxicity of the mixture was tested against four human tumor cell lines in the following
cultures: MDA-MB-435 (melanoma), HCT-8 (colon), HL-60 (leukemia), and SF-295 (glioblastoma), and
displayed IC50 values ranging from 8.08 to 23.58 lg/mL. Additional assays were performed in order to
investigate the mechanism of action of the mixture (1 + 2) against the human leukemia cell line HL-60.
The results suggested that the mixture suppressed leukemia growth and reduced cell survival, triggering
both apoptosis and necrosis, depending on the concentration.
 2010 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Cancer affects about two hundred different types of cells. The
most prominent characteristics of the disease are lack of control
in cell proliferation, cell differentiation, and cell mortality, invading
either organs or tissues.1 There are many difﬁculties in the treat-
ment of cancer, but the most concerning are drug resistance, toxic-
ity and low speciﬁcity.
The potential to ﬁnd out promising molecules in the Cerrado
biome to several applications have alreadybeendemonstrated in di-
verse biological models.2–5 Four hundred and twelve crude extracts
from Brazilian Cerrado native plants were previously assayed
against cancer cell lines.3 The hexane extract from Kielmeyera coria-
ceaMart. &Zucc. (Calophyllaceae) root bark, known inBrazil as ‘pau-
santo’, showed signiﬁcant activity.3 This extract showed IC50 values
of 10.6 lg/mL for MDA-MB-435 (melanoma), 5.2 lg/mL for HCT-8
(colon), 15.4 lg/mL for HL-60 (leukemia), and 6.4 lg/mL for
SF-295 (glioblastoma) cells, and was, therefore, selected for this
study.ário Darcy Ribeiro, Asa Norte,
3307 3046; fax: +55 61 3107
Elsevier OA license.2. Results and discussion
Bioassay-guided fractionation of the hexane root bark extract of
K. coriacea resulted in a mixture of two compounds, whose physical
and spectral data revealed the presence of a monomer of
d-tocotrienol (1) and a novel d-tocotrienol peroxy-dimer (2).
2.1. Characterization of d-tocotrienol (1) and d-tocotrienol
peroxy-dimer (2)
Compound 1 was obtained as a brown viscous liquid. Spectral
data, mainly 1D and 2D NMR 1H (1D 1H and 2D 1H-1H-COSY), 13C
(CPD = Composite Pulse in broadband Decoupling and DEPT), HSQC
(Heteronuclear Single Quantum Coherence allowed the assignment
of all hydrogenated carbon atoms), HMBC (Heteronuclear Multiple
Bond Correlation involving two, 2JCH, and three, 3JCH, bonds,
Table 1), NOESY (Nuclear Overhauser Effect Spectroscopy) and mass
(EI-MS, 70 eV) spectra, compared with the literature values6 were
used to characterize 1 as d-tocotrienol, including the same relative
stereochemistry. The results of the extensive applications of 1D and
2D NMR were also used to establish unequivocally the complete 1H
and 13C resonance assignments, as summarized in Table 1.
The mass spectrum exhibited a base peak at m/z 396 (EI-MS,
70 eV) corresponding to d-tocotrienol (1) (Fig. 1). The presence of
the peak at m/z 791, compatible with a molecular formula of
Table 1
NMR data for d-tocotrienol (1) and d-tocotrienol peroxy-dimer (2) (in CDCl3 and pyridine-d5 as solvents). Residual CHCl3/CDCl3 or pyridine-d5 used as reference. Chemical shifts
(d, ppm) and coupling constants (J, Hz, in parenthesis)a
Atom number 2 1
HSQC HMBC
dC dH dC dH
2JCH
3JCH
2/200 75.74 — 75.52 — 2H-3; 2H-10; 3H-2a 2H-4; 2H-20
2a/200a 24.55 1.30, 3H, s 24.21 1.25, 3H, s 2H-3; 2H-10
3/300 32.19 1.75, 2H, m 31.58 1.79, 2H, m 2H-4 3H-2a
4/400 23.20 2.73, 2H, m 22.68 2.70, 2H, m 2H-3 H-5
5/500 114.20 6.87, 1H, d, 2.6 112.84 6.37, 1H, d, 2.6 2H-4; H-7
6/600 151.74 — 148.00 — H-5; H-7
7/700 117.30 7.01, 1H, d, 2.6 115.90 6.49, 1H, d, 2.6 H-5; 3H-8a
8/800 127.38 — 127.91 — 3H-8a
8a/800a 16.48 2.32, 3H, s 16.19 2.14, 3H, s H-7
9/900 145.71 — 146.16 — H-5; H-7; 2H-4; 3H-8a
10/1000 122.02 — 121.42 — 2H-4 2H-3
10/1000 40.40 1.67, 1H, m and 1.61, 1H, m 39.90 1.65, 2H, m and 1.55, 2H, m 2H-20 2H-3; 3H-2a
20/2000 22.99 2.12-2.16, 2H, m 22.37 2.09, 2H, m 2H-10; H-30
30/3000 125.31 5.16, 1H, t, 6.7 124.51 5.16, 1H, t, 6.7 2H-20 3H-40a; 2H-50
40/4000 b — 135.15 — 2H-50; 3H-40a 2H-20; 2H-60
40a/4000a 16.82 1.69, 3H, m 16.24 1.61, 3H, s H-12; 2H-50
50/5000 40.39 1.98–2.01, 2H, m 39.90 1.99, 2H, m H-30; H-70; 3H-40a
60/6000 27.46 2.07–2.10, 2H, m 26.96 2.05, 2H, m 2H-50
70/7000 125.11 5.13, 1H, t, 6.0 124.50 5.12, 1H, m 2H-60 2H-50; 2H-90
80/8000 b — 135.31 — 3H-80a; 2H-90 2H-60; 2H-100
80a/8000a 16.33 1.69, 3H, s 16.06 1.62, 3H, s H-70; 2H-90
90/9000 40.40 1.98–2.01, 2H, m 39.90 1.99, 2H, m H-70; H-110
100/10000 27.30 2.12–2.16, 2H, m 26.80 2.05, 2H, m 2H-90; H-110
110/11000 125.40 5.12, 1H, t, 6.0 124.62 5.12, 1H, m 2H-100 2H-90; 3H-120a; 3H-120b
120/12000 131.56 — 131.44 — 3H-120a; 3H-120b 2H-100
120a/12000a 18.10 1.61, 3H, s 17.87 1.62, 3H, s H-110; 3H-120b
120b/12000b 26.14 1.70, 3H, s 25.89 1.70, 3H, s H-110; 3H-120a
a Number of hydrogen bound to carbon atoms deduced by comparative analysis of {1H}- and DEPT-13C NMR spectra. Chemical shifts and coupling constants (J) were
obtained from 1D 1H NMR spectrum. 1H–1H-COSY experiment was also used to make the assignments. Superimposed 1H signals are described without multiplicity and
chemical shifts were deduced by 1H–1H-COSY, HSQC, and HMBC spectra.
b Superimposed with pyridine signal.
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peroxy-dimer (2) (Fig. 1).
Compound 2 was obtained as a brown viscous liquid after sep-
aration through HPLC chromatography (265 nm) from the mixture
of both d-tocotrienol (1) and d-tocotrienol peroxy-dimer (2).
Comparative analysis of the NMR spectra of 1 and 2 (Table 1) re-
vealed as signiﬁcant differences the changes observed in the 1H
and 13C of the signals of the CH-7 [dC 115.90 (1)/117.30 (2),
DdC = 1.40 ppm], C-6 [dC 148.00 (1)/151.78 (2), DdC = 3.78 ppm]
and CH-5 [dC 112.84 (1)/114.20 (2), DdC = 1.36 ppm] and the
hydrogen atoms H-7 [dH 6.49 (1)/7.01 (2), DdH = 0.52 ppm], H-5
[dH 6.37 (1)/6.87 (2), DdH = 0.50 ppm], in the agreement with the
deshielding caused by the decreasing electronic donating ability
of the C-6 hydroxyl after the formation of the peroxy bridge in 2.
This deduction in combination with the additional NMR data
spectral (Table 1) and mass spectrum of 2 (m/z 791 [M]+, Scheme
1) were used to establish the structure of this new compound
isolated from K. coriacea as the d-tocotrienol peroxy-dimer (2,
Fig. 1). These spectral data were also used to eliminate structural
dimer alternatives I, II, and III (Fig. 1). Thus, the tocotrienols iso-
lated from K. coriacea were characterized as d-tocotrienol mono-
mer, 2,8-dimethyl-2-[(3E,7E)-4,8,12-trimethyltrideca-3,7,11-trienyl]
chroman-6-ol (1), and d-tocotrienol peroxy-dimer, bis-(6,60-O-O)-
2,8-dimethyl-2-[3(E),7(E),4,8,12-trimethyl-trideca-3,7,11-trienyl]-
chromane (2), shown in Figure 1.
2.2. Evaluation of d-tocotrienols cytotoxicity
The cytotoxicity of the test mixture (1 + 2) was investigated
against four tumor cell lines: HL-60 (leukemia), HCT-8 (colon),
MDA-MB-435 (melanoma), and SF-295 (glioblastoma) cell lines.To access the selectivity of the tested compounds, cytotoxicity
was further evaluated against two normal cell lines: NIH-3T3 and
peripheral blood mononuclear cells (PBMC).
These four tumor cell lines were incubated with increasing con-
centrations of the mixture (1 + 2) for 72 h at 37 C and analyzed
using the tetrazolium salt colorimetric MTT assay. Signiﬁcant
dose-dependent suppression of cell growth was observed. Table
2 displays the IC50 values, which ranged from 8.08 to 23.58 lg/
mL. In HCT-8 and MDA-MB-435 cells, the crude extract was more
active. These results agree with previous reports that d-tocotrie-
nols exert stronger anti-proliferative effects against human hepa-
toma Hep3B cells,7 HepG2 cells,8 and murine hepatoma MH134
cells both in vitro and in vivo.9 In order to study the mechanisms
involved in the cytotoxicity of d-tocotrienols, the mixture (1 and
2) at concentrations of 5 and 10 lg/mL was tested in HL-60 cells.
Cell viability was reduced at both concentrations as demon-
strated by the trypan blue exclusion test (Fig. 2A). However, only
the highest concentration of the mixture (1 + 2) caused a signiﬁ-
cant increase in the number of non-viable cells. Additionally,
DNA synthesis was affected after treatment with the mixture
(1 + 2), resulting in a lower amount of cell division that corrobo-
rated with the trypan blue exclusion test and MTT assay. The mix-
ture (1 + 2) inhibited BrdU incorporation by 23.4% and 95.9% at the
concentrations of 5 and 10 lg/mL, respectively (Fig. 2B). The doxo-
rubicin positive control reduced DNA synthesis by 47.9%.
Cell cycle progression was determined using ﬂow cytometry.
These results suggest that the mixture may preferentially stimu-
late cells in the G2/M phase to undergo apoptosis more readily.
At the 5 lg/mL concentration, the number of cells in G0/G1 phase
and S phase remained constant. However, there were only 8.78%
in the G2/M phase, as opposed to 15.49% in the negative control.
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Figure 1. Molecular structure of d-tocotrienol monomer (1) and d-tocotrienol peroxy-dimer (2) and discarded structural possibilities showing C–C bridges (I, II, and III).
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icantly lower in all phases (Table 3). In addition, both concentra-
tions caused signiﬁcant internucleosomal DNA fragmentation
(Fig. 3A). The doxorubicin positive control also demonstrated sig-
niﬁcant internucleosomal DNA fragmentation.
Understanding the regulatory mechanism through the control
of cell cycle progression and growth could play a critical role in
the development of new agents to prevent and treat cancer. It
has been demonstrated that d-tocotrienol treatment led to the
down-regulation of cyclin B1 and CDK1, in MDA-MB-231 breast
cancer cells, that are required for the progression of the cell cycle
through the G2/M checkpoint. Negative regulation of these cell
cycle promotes an increase in G1 and G2/M arrest following the
addition of d-tocotrienol.10 This work suggests that the mixture
of d-tocotrienol (1) and its peroxy-dimer (2) may preferentially
stimulate cells in the G2/M phase to undergo apoptosis in human
leukemia cell line HL-60.
Additional experiments were performed to investigate whether
the inhibitory growth activity of the mixture (1 + 2) was related to
the induction of apoptosis or necrosis. The reduction of the number
of cells was also observed by ﬂow cytometry analyses in both con-
centrations (Fig. 3B). On the other hand, the mixture (1 + 2) only
induced disruption of membrane integrity at 10 lg/mL (Fig. 3C).
Furthermore, the mixture caused cell shrinkage at both concentra-
tions (data not shown). This was supported by a decrease in
forward light scatter (FSC) and nuclear condensation as observed
by a transient increase in side scatter (SSC). Both of the aforemen-
tioned morphological modiﬁcations are compatible with cell
apoptosis. The mixture also induced mitochondrial depolarizationin HL-60 cells, which was observed by the incorporation of
rhodamine 123 (Fig. 3D). Doxorubicin also induced apoptotic
effects.
Morphological examination of treated and untreated HL-60
cells revealed severe drug-mediated changes, as observed by light
microscopy (qualitative analyses, Fig. 4) and ﬂuorescent micros-
copy (quantitative analyses, Fig. 5). In light microscopy analyses,
HL-60 cells incubated with the mixture (1 + 2) at 5 lg/mL showed
morphologies consistent with apoptosis, including chromatin con-
densation and fragmentation of the nuclei. However, these cells at
a concentration of 10 lg/mL were induced to a reduction in the
volume, destabilization of the plasma membrane and pyknotic
nuclei, all of which are morphological features consistent with
necrosis. In ﬂuorescent microscopy analyses, the percentage of via-
ble, apoptotic and necrotic cells were calculated. After treatment of
HL-60 cells with the mixture for 24 h at 37 C, an increasing
number of apoptotic and necrotic cells were observed (p <0.05).
In addition, the doxorubicin-treated cells also showed apoptotic
characteristics.
Apoptosis induction is arguably the most potent defense against
cancer progression. Researchers have demonstrated that tocotrie-
nols induce apoptosis in cancer cell lines.11,12 However, the exact
mechanisms triggered by tocotrienols have not been fully eluci-
dated to date. Tocotrienols induce caspase-9 expression in human
colon carcinoma cells via the activation of p53 and an increase in
the Bax/Bcl-2 ratio.13 d-Tocotrienol-induced apoptosis also seemed
to be involved in the activation of transforming growth factor
signaling pathways growth factor-b, Fas and JNK in human breast
cancer cells.14 Sakai et al.7 reported that caspase-3, caspase-8 and
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Table 2
Cytotoxic activity of the mixture (1 + 2) on human cancer cell lines
Cell line Histotype Mixture (1 + 2)
(lg/mL)
Doxorubicin
(lg/mL)
HL-60 Leukemia 8.08 0.02
6.53–9.99 0.01–0.03
HCT-8 Colon 13.02 0.01
11.55–16.27 0.01–0.02
SF-295 Glioblastoma 23.58 0.24
20.11–26.05 0.17–0.36
MDA-MB-435 Melanoma 16.39 0.48
14.56–19.12 0.34–0.66
Doxorubicin was used as a positive control. Data are presented as IC50 values and
95% conﬁdence interval (CI 95%) from three independent experiments, performed in
duplicate.
Table 3
Effect of the mixture (1 + 2) on different stages within the HL-60 cell cycle determined
by ﬂow cytometry using propidium iodide, triton X-100, and citrate after 24 h at 37 C
Sample Concentration
(lg/mL)
Phase of the cell cycle (%)
G0/G1 S G2/M
Control — 56.84 ± 1.25 18.12 ± 0.43 15.49 ± 1.04
Doxorubicin 0.3 13.86 ± 2.26a 1.17 ± 0.18a 0.481 ± 0.07a
1 + 2b 5 51.56 ± 1.99 17.00 ± 1.06 8.78 ± 0.62a
10 22.47 ± 2.73a 2.00 ± 0.51a 0.72 ± 0.15a
Negative control (control) was treated with the vehicle used for diluting the tested
substance. Doxorubicin was used as a positive control. Data are presented as mean
values ± SEM from three independent experiments performed in triplicate. Five
thousand events were analyzed in each experiment.
a p <0.05 compared to control by ANOVA followed by Student Newman Keuls test.
b 1 + 2 d-Tocotrienol monomer (1) and d-tocotrienol peroxy-dimer (2) mixture.
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Figure 2. Effect of themixture (1 + 2)onHL-60 cell proliferation after 24 h incubation.
(A) Cell proliferation determined by trypan blue staining. (B) Cell proliferation
determined by 5-bromo-20-deoxyuridine (BrdU) incorporation. Negative control (C)
was treated with the vehicle used for diluting the tested substance. 0.3 mg/mL
doxorubicin was used as a positive control (D). Data are presented as mean
values ± SEM from three independent experiments performed in triplicate. *p <0.05
compared to control by ANOVA followed by Student Newman Keuls test.
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Hep3B cells, and that Bax and Bid participated in the regulation
of apoptosis induction. Ahn et al.15 showed that c-T3 inhibited
the NF-jB activation pathway through inhibition of RIP and
TAK1, leading to suppression of antiapoptotic gene products and
potentiation of apoptosis. Therefore, the mixture of d-tocotrienol
(1) and its peroxy-dimer (2) induce apoptosis via mitochondrial
pathways, and necrosis, depending on the concentration used
against the human leukemia cell line HL-60. Evaluation of the mix-
ture in NIH-3T3 mammalian ﬁbroblast cells and in lymphocytes
showed IC50 values of 15.43 and 12.11 lg/mL, respectively, which
indicated there was no selectivity to cancer cells. However, natural
products could be used in the design of a more potent and selective
agent.
3. Conclusion
A mixture of d-tocotrienol (1) and its peroxy-dimer (2) from the
K. coriacea hexane root bark extract was found to be active against
MDA-MB-435 (melanoma), HCT-8 (colon), HL-60 (leukemia), and
SF-295 (glioblastoma) cells. The mixture (1 + 2) suppressed leuke-
mia growth and reduced cell survival, triggering both apoptosis
and necrosis, at concentrations of 5 and 10 lg/mL, respectively.
4. Experimental
4.1. General experimental procedures
The mass spectra were obtained using a Hewlett–Packard 5971
mass spectrometer by electron impact ionization (70 eV). 1H and13C nuclear magnetic resonance (NMR) were recorded on a Bruker
Avance DRX-500 (500 MHz for 1H and 125 MHz for 13C). Chemical
shifts are given in ppm relative to residual CHCl3/CDCl3 (dH 7.24/
dC 77.23, central signal of the triplet related to carbon) or pyridine-
d5 [dH 8.74 (H-2/H-6)/dC 150.6 (C-2/C-6), dH 7.58 (H-4)/dC 135.9
(C-4) and dH 7.22 (H-3/H-5)/dC 123.9 (C-3/C-5)]. Silica Gel 60
(2–25 mesh, Merck) was used for analytical TLC. Silica Gel 60
(40–63 mesh, Merck) was used for column ﬂash chromatography.
All compounds were visualized on TLC by spraying with vanillin/
perchloric acid/EtOH, followed by heating. This mixturewas further
puriﬁed through preparative HPLC (Waters-1525) connected to a
detector PDAWaters-2996 (265 nm) with XTerra-SiO2 column
(4.6  250 mm, 5 lM).
4.2. Plant material
K. coriaceaMart. & Zucc. (Calophyllaceae) was collected from the
Cerrado biome, in the outskirts of Brasília, Distrito Federal, Brazil,
in 2005, and was identiﬁed by Dr. José Elias de Paula, from the
Biology Institute of the University of Brasília. A voucher specimen
was deposited in the Herbarium of said University, under the
reference: J. Elias de Paula (UB) 3745.
4.3. Extraction and isolation
Dried and powdered root bark (340 g) of K. coriaceawas submit-
ted to successive extractions with hexane, through a maceration
process, to yield a crude extract (28.85 g) following evaporation
of the solvent under reduced pressure at 40 C. An aliquot of this
extract (4 g) was fractionated using silica gel by elution with a gra-
dient of cyclohexane–EtOAc to afford 10 fractions (F1–F10) based
on TLC behavior.
Fractions F3 and F4 showed higher cytotoxicity at 50 lg/mL. Re-
sults are stated for F3 and F4, respectively, against the following
cell lines: SF-295 (95.87% and 78.83%), HCT-8 (96.94% and
80.39%), and MDA-MB-435 (98.87% and 96.02%).
Chromatography was performed on fraction 4 (F4, 900 mg)
using silica gel with a gradient of hexane, CH2Cl2, and MeOH. Four-
teen sub-fractions (F4–1 to F4–14) were collected. Successive puri-
ﬁcations of sub-fraction F4–6 (220.6 mg) using silica gel with a
gradient of hexane–CHCl3 yielded a mixture of two compounds.
50.0 mg of the mixture was further puriﬁed through preparative
HPLC using hexane/EtOAc (60:40) as eluent, to give the pure com-
pounds 1 (41.35 mg; tR = 8.3 min) and 2 (4.4 mg; tR = 6.5 min).
The molecular formulas of the two aforementioned compounds
were deduced to be C27H40O2 corresponding to d-tocotrienol (1),
and C54H78O4 corresponding to d-tocotrienol peroxy-dimer (2).
4.3.1.d-Tocotrienol, {1, 2,8-dimethyl-2-[3(E),7(E),4,8,12-trimethyl-
trideca-3,7,11-trienyl]-chroman-6-ol}
Brown viscous liquid; ½a20D 4 (c 0.05, CHCl3); EI-MS m/z: 396
[M+], 259, 217, 203, 192, 177, 163, 149, 137, 109, 95, 81, 69, 55,
and 41. Table 1 presents 1H and 13C NMR spectral data.
4.3.2. d-Tocotrienol peroxy-dimer {2, bis-(6,60-O-O)-2,8-dimethyl-
2-[3(E),7(E),4,8,12-trimethyl-trideca-3,7,11-trienyl]-chromane}
Brown viscous liquid; EI-MS m/z: 791 [M+], 396, 259, 217, 203,
192, 177, 163, 149, 137, 109, 95, 81, 69, 55, and 41. Table 1
presents 1H and 13C NMR spectral data.
4.4. Cell lines and cell cultures
Thecell linesused in thiswork—MDA-MB-435 (melanoma),HCT-
8 (colon),HL-60 (leukemia), andSF-295 (glioblastoma)—wereall ob-
tained from the National Cancer Institute (Bethesda, MD, USA).
These cells were maintained in RPMI 1640 medium supplemented
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Figure 3. Effect of the mixture (1 + 2) on HL-60 cells after 24 h incubation determined by ﬂow cytometry after 24 h at 37 C. (A) Internucleosomal DNA fragmentation, (B) cell
proliferation, (C) cell membrane integrity, and (D) mitochondrial transmembrane potential. Negative control (C) was treated with the vehicle used for diluting the tested
substance. 0.3 mg/mL doxorubicin was used as a positive control (D). Data are presented as mean values ± SEM from three independent experiments performed in triplicate.
*p <0.05 compared to control by ANOVA followed by Student Newman Keuls test.
Figure 4. Light Microscopy (400) of hematoxylin/eosin-stained HL-60 cells. Untreated cells—negative control (A), 0.3 lg/mL doxorubicin—positive control (B), mixture
(1 + 2) at 5 lg/mL (C), and at 10 lg/mL (D). Black arrows show chromatin condensation or nuclear fragmentation, and white arrows show destabilization of the plasma
membrane or pyknotic nuclei.
628 M. L. de Mesquita et al. / Bioorg. Med. Chem. 19 (2011) 623–630
020
40
60
80
100
C D
Viable cells Necrotic cellsApoptotic cells
5 10 (µg/mL)
mixture (1 + 2)
*
*
*
*
*
*
*
C
el
l n
um
be
r (
%
)
Figure 5. Fluorescence microscopy of HL-60 cells after 24 h at 37 C using acridine
orange and ethidium bromide. Negative control (C) was treated with the vehicle
used for diluting the tested substance. 0.3 mg/mL doxorubicin was used as a
positive control (D). Data are presented as mean values ± SEM from three
independent experiments performed in triplicate. *p <0.05 compared to control
by ANOVA, followed by Student Newman Keuls test.
M. L. de Mesquita et al. / Bioorg. Med. Chem. 19 (2011) 623–630 629with 10% fetal bovine serum, 2 mM glutamine, 100 U/mL penicillin,
100 lg/mL streptomycin at 37 C with 5% CO2.
4.5. Proliferation assay
4.5.1. Inhibition of tumor cell proliferation
Cytotoxicity of the test mixture (1 + 2) was investigated against
HL-60, HCT-8, MDA-MB-435, and SF-295. For all experiments,
these cells were transferred into 96-well plates (105 cells/well for
adherent cells or 0.5  105 cells/well for suspended cells) in
100 lL of medium. After 24 h, serial dilutions (from 0.02 to
25.0 lg/mL) of the test mixture dissolved in DMSO were added
to each well (using the HTS—high-throughput screening—Biomek
3000—Beckman Coulter, Inc. Fullerton, CA, USA) and incubated
for 72 h. Doxorubicin (Sigma–Aldrich Co., St. Louis, MO, USA) was
used as a positive control. Tumor cell growth was quantiﬁed by
the ability of living cells to reduce the yellow dye 3-(4,5-di-
methyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT)
to a purple formazan product.16 At the end of the incubation, plates
were centrifuged and the medium was replaced with fresh med-
ium (150 lL) containing MTT (0.5 mg/mL). Three hours later, the
MTT formazan product was dissolved in 150 lL DMSO, and the
absorbance measured using a multi-plate reader (DTX 880 Multi-
mode Detector, Beckman Coulter, Inc., Fullerton, CA, USA). Cyto-
toxic activity was quantiﬁed as the percentage of control
absorbance of reduced dye at 595 nm.
Cytotoxicity was evaluated over a concentration range of 300–
9.4 lg/mL for NIH-3T3 cells. These cells were seeded in 96-well
plates at a density of 8  103 cells in Dulbecco’s Modiﬁed Eagle
Medium (DMEM; Gibco) containing 10% stain buffer (FBS) (v/v)
overnight at 37 C in 5% CO2. The medium was changed and incu-
bated with or without different concentrations of the mixture
(1 + 2) at 37 C in 5% CO2. After 24 h, the cell viability was deter-
mined by MTT assay.16 Brieﬂy, 15 lL of MTT solution (5 mg/mL
in PBS) were added to each well. After 3 h of incubation at 37 C
in 5% CO2, the culture media was aspirated and 100 lL of DMSO
were added. The absorbance was monitored using a spectropho-
tometer with a microplate reader at a wavelength of 595 nm.
Peripheral blood mononuclear cells (PBMC) were also tested.
Heparinized blood from healthy, non-smoking donors who had
not taken any drugs for at least 15 days prior to sampling was
collected, and the PBMC were isolated via a standard method of
density-gradient centrifugation over Ficoll-Hypaque. PBMC were
washed and re-suspended at a concentration of 3  106 cells/mLin RPMI 1640 medium supplemented with 20% fetal bovine serum,
2 mM glutamine, 100 U/mL penicillin, and 100 lg/mL streptomy-
cin at 37 C with 5% CO2. Phytohemagglutinin (4%) was added at
the beginning of the experiment.
4.6. Study of the cytotoxic mechanism affecting the leukemia
cell (HL-60)
The following experiments were performed in order to eluci-
date the mechanism(s) involved in the cytotoxic action of the mix-
ture (1 + 2) using HL-60 cells (3  105 cells/mL), since it was the
most sensitive cell line. Concentrations of 5 and 10 lg/mL were
analyzed. 0.3 lg/mL doxorubicin was used as a positive control.
4.6.1. Trypan blue exclusion test
Cell viability was determined using the trypan blue exclusion
test. Aliquots were removed from cultures after 24 h, and cells that
excluded the trypan blue dye were counted in a Neubauer
chamber.
4.6.2. Measurement of DNA synthesis
Ten microliters of 5-bromo-20-deoxyuridine (BrdU, 10 mM) was
added to each well and the plate was incubated for 3 h at 37 C be-
fore completing the 24 h period of drug exposure. To assay the
amount of BrdU incorporated into DNA, cells were harvested,
transferred to cytospin slides, and allowed to dry for 2 h at room
temperature. Cells that had incorporated BrdU were labeled by
direct peroxidase immunocytochemistry utilizing chromogen
diaminobenzidine. Slides were counterstained with hematoxylin,
mounted, and cover slipped. Evaluation of BrdU positivity was
performed using light microscopy (Olympus, Tokyo, Japan). Two
hundred cells were counted per sample to determine the percent-
age of positive cells.4.6.3. Cell cycle distribution and internucleosomal DNA
fragmentation analyses
Based on the procedure of Nicoletti et al.,17 HL-60 cells (3  105)
were incubated at 37 C for 24 h, without light, in a lysis solution
containing 0.1% citrate, 0.1% Triton X-100, and 50 lg/mL propidium
iodide. Cell ﬂuorescencewas then determined using ﬂow cytometry
in a Guava EasyCyte™ Mini System cytometer (Guava Technolo-
gies, Inc., Industrial Blvd. Hayward, CA, USA) and the CytoSoft 4.1
software. Five thousand events were evaluated per experiment
and cellular debris was omitted from the analysis. All DNA that
was sub-diploid in size (sub-G1) was considered the result of inter-
nucleosomal DNA fragmentation.4.6.4. Cell membrane integrity
Cell membrane integrity was evaluated by the exclusion of
2 lg/mL propidium iodide. Cell ﬂuorescence was determined using
ﬂow cytometry as in Section 4.6.3. Five thousand events were
evaluated per experiment and cell debris was omitted from the
analysis.
4.6.5. Measurement of mitochondrial transmembrane potential
Mitochondrial transmembrane potential was determined by the
retention of rhodamine 123 dye by HL-60 cells. Cells were washed
with phosphate-buffered saline (PBS), incubated with rhodamine
123 (5 lg/mL) at 37 C for 15 min without light, and washed twice
with phosphate butter solution (PBS). The cells were then incu-
bated again in PBS at 37 C for 30 min without light and ﬂuores-
cence was then measured using ﬂow cytometry as in Section
4.6.3. Five thousand events were evaluated per experiment and cell
debris was omitted from the analysis.
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To evaluate nuclear morphology, treated cells were harvested,
transferred to cytospin slides, ﬁxed with methanol for 30 s, and
stained with hematoxylin–eosin.
4.6.7. Morphological analysis using ﬂuorescence microscopy
After incubation, cells were centrifuged and re-suspended in
25 lL PBS. 1 lL of an aqueous solution of 100 lg/mL acridine or-
ange/ethidium bromide was added and the cells were observed un-
der a ﬂuorescence microscope (Olympus, Tokyo, Japan). Three
hundred cells were counted per sample, and were classiﬁed as fol-
lows: viable cells, apoptotic cells and necrotic cells.
4.7. Statistical analysis
Data are presented as IC50 values with their 95% conﬁdence
intervals (CI 95%) obtained by nonlinear regression, or as mean ±
SEM calculated using the GRAPHPAD program (Intuitive Software
for Science, San Diego, CA). The differences between experimental
groups were compared by one-way analysis of variance (ANOVA)
followed by Student Newman Keuls test.
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